AIIMS chief Randeep Guleria has said that India must hike vaccine production in a big way and complement it with a holistic global procurement approach to meet its Covid inoculation targets.
Highlights
India has so far reported at least 8,848 mucormycosis cases, as per an IANS report.
Black Fungus or ‘mucormycosis’ is a rare fungal infection that is caused by a fungus named mucor, found on wet surfaces.
Doctors recommend amphotericin B or ampho-B , an anti-fungal intravenous injection, for the treatment of the infection.
New Delhi: As India grapples with the second wave of the COVID-19, rising cases of mucormycosis or ‘black fungus’ infection are becoming worrisome.
India has so far reported at least 8,848 mucormycosis cases, as per an IANS report. While AIIMS Delhi Director Dr Randeep Guleria was quoted as saying by ANI, The Covid-19-linked infection has claimed more than 7,000 lives in the country.
Director of All India Institute Of Medical Sciences (AIIMS) Dr Randeep Guleria on Sunday said that the medical treatment for Black Fungus (Mucormycosis) is more prolonged as compared to COVID-19 pandemic. Guleria was speaking at India TV s #JeetegaIndiaHaaregaCorona conclave.
URL copied
Steroids a strict no-no for mild Covid patients: AIIMS Director Dr Randeep Guleria
Amid rise of mucormycosis (black fungus) infection, diabetic patients are advised to frequently monitor and control their blood sugar levels. Diabetic patients (those with uncontrolled diabetes), steroid usage and being Corona positive, a combination of these factors places one under risk of getting mucormycosis. Therefore, diabetic patients should regularly monitor and control their blood sugar levels.
Mucormycosis or black fungus infection is not a new disease and it was reported even before the pandemic. Its incidence, however, was very low. Now, owing to Covid-19, this rare but fatal fungal infection is being reported in large numbers.